$NXEN
Nexien Biopharma Inc

2024 Q1 Form 10-Q Financial Statement

#000149315224007096 Filed on February 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2022 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.95K $13.44K $73.03K
YoY Change -77.01% -81.6% -65.79%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $15.95K $13.44K $73.03K
YoY Change -77.01% -81.6% -65.79%
Operating Profit
YoY Change
Interest Expense -$37.22K -$11.08K -$20.56K
YoY Change 255.15% -46.11% 206.87%
% of Operating Profit
Other Income/Expense, Net -$37.22K -$11.08K -$20.56K
YoY Change 255.18% -46.1% 206.96%
Pretax Income -$53.16K -$24.52K -$93.59K
YoY Change -33.43% -73.8% -57.5%
Income Tax
% Of Pretax Income
Net Earnings -$53.16K -$24.52K -$93.59K
YoY Change -33.42% -73.8% -57.49%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 67.47M shares 65.27M shares 62.02M shares
Diluted Shares Outstanding 66.38M shares 65.11M shares 61.92M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.07K $2.620K $68.99K
YoY Change -81.42% -96.2% 2246.6%
Cash & Equivalents $10.07K $2.619K $68.99K
Short-Term Investments
Other Short-Term Assets $4.200K $0.00 $7.980K
YoY Change 5.26% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.27K $2.619K $76.97K
YoY Change -75.48% -96.6% 2518.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $14.27K $2.619K $76.97K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $14.27K $2.619K $76.97K
YoY Change -75.48% -96.6% 2518.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $44.53K $36.36K $21.29K
YoY Change 98.71% 70.78% 224.54%
Accrued Expenses $53.40K $45.00K $45.00K
YoY Change 18.67% 0.0% 28.57%
Deferred Revenue
YoY Change
Short-Term Debt $241.6K $235.5K $213.0K
YoY Change 9.29% 10.54% 794.96%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $339.6K $316.8K $279.3K
YoY Change 17.7% 13.43% 327.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $339.6K $316.8K $279.3K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $339.6K $316.8K $279.3K
YoY Change 17.7% 13.43% 327.25%
SHAREHOLDERS EQUITY
Retained Earnings -$11.45M -$11.39M -$11.12M
YoY Change 2.2% 2.45%
Common Stock $6.747K $6.527K $6.202K
YoY Change 7.49% 5.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$325.3K -$314.2K -$202.3K
YoY Change
Total Liabilities & Shareholders Equity $14.27K $2.619K $76.97K
YoY Change -75.48% -96.6% 2518.06%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2022 Q4
OPERATING ACTIVITIES
Net Income -$53.16K -$24.52K -$93.59K
YoY Change -33.42% -73.8% -57.49%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$20.95K -$12.53K -$32.16K
YoY Change 41.75% -61.04% 104.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 28.40K 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -20.95K -12.53K -32.16K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 28.40K 0.000 0.000
Net Change In Cash 7.450K -12.53K -32.16K
YoY Change -150.41% -61.04% 4188.0%
FREE CASH FLOW
Cash From Operating Activities -$20.95K -$12.53K -$32.16K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0001625288
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 NXEN Stock Payable
StockPayable
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2022Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Stock Issued1
StockIssued1
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55320
dei Entity Registrant Name
EntityRegistrantName
NEXIEN BIOPHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2049376
dei Entity Address Address Line1
EntityAddressAddressLine1
4340 E Kentucky Ave.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 206
dei Entity Address City Or Town
EntityAddressCityOrTown
Glendale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80246
dei City Area Code
CityAreaCode
(303)
dei Local Phone Number
LocalPhoneNumber
495-7583
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67472196 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2619 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35147 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7980 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2619 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
43127 usd
CY2023Q4 us-gaap Assets
Assets
2619 usd
CY2023Q2 us-gaap Assets
Assets
43127 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
36358 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
23643 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
8963 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
316812 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
295134 usd
CY2023Q4 us-gaap Liabilities
Liabilities
316812 usd
CY2023Q2 us-gaap Liabilities
Liabilities
295134 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65272196 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65272196 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64022196 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64022196 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6527 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6402 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11074076 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10986201 usd
CY2023Q2 NXEN Stock Payable
StockPayable
50750 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11394796 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11295360 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-314193 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-252007 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2619 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43127 usd
CY2023Q4 us-gaap Professional Fees
ProfessionalFees
5625 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
6160 usd
us-gaap Professional Fees
ProfessionalFees
21165 usd
us-gaap Professional Fees
ProfessionalFees
21420 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7811 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66872 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
54266 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
125927 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
13436 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
73032 usd
us-gaap Operating Expenses
OperatingExpenses
75431 usd
us-gaap Operating Expenses
OperatingExpenses
147347 usd
CY2023Q4 us-gaap Interest Expense Other
InterestExpenseOther
7521 usd
CY2022Q4 us-gaap Interest Expense Other
InterestExpenseOther
2422 usd
us-gaap Interest Expense Other
InterestExpenseOther
15042 usd
us-gaap Interest Expense Other
InterestExpenseOther
4843 usd
CY2023Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3561 usd
CY2022Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
18138 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8963 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
36276 usd
CY2023Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11082 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20560 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24005 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41119 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-24518 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-93592 usd
us-gaap Net Income Loss
NetIncomeLoss
-99436 usd
us-gaap Net Income Loss
NetIncomeLoss
-188466 usd
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65107361 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65107361 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61915053 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61915053 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64840502 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64840502 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61493507 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61493507 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-252007 usd
CY2023Q3 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
35000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-74918 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-290800 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-24518 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-314193 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-117605 usd
CY2022Q3 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-94874 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-160604 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-160604 usd
CY2022Q4 NXEN Common Stock Issuable To Officers
CommonStockIssuableToOfficers
50750 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1125 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-93592 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-202321 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-202321 usd
us-gaap Net Income Loss
NetIncomeLoss
-99436 usd
us-gaap Net Income Loss
NetIncomeLoss
-188466 usd
NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
2250 usd
NXEN Imputed Interest On Related Party Advances
ImputedInterestOnRelatedPartyAdvances
2250 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
35000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
101500 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
8963 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
10804 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
25472 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7980 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
360 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12715 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
893 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32528 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47907 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32528 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47907 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35147 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
116898 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2619 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68991 usd
us-gaap Stock Issued1
StockIssued1
50750 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
11394796 usd
CY2023Q4 NXEN Working Capital Deficit
WorkingCapitalDeficit
314193 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_z4YrzBK1eDsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_zdPOSIUEzReg">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7995000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y2M12D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Advertising Expense
AdvertisingExpense
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTqXW2AVFzMf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zHGX9VpOLZI9">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2023Q2 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
CY2023 NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y7M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
5529409 shares
CY2023Q4 NXEN Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageExercisePrice
0.0429
NXEN Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y10M6D
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
8963 usd
NXEN Amortization Of Financing Costs And Discounts Related Party
AmortizationOfFinancingCostsAndDiscountsRelatedParty
10804 usd
CY2023Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure

Files In Submission

Name View Source Status
0001493152-24-007096-index-headers.html Edgar Link pending
0001493152-24-007096-index.html Edgar Link pending
0001493152-24-007096.txt Edgar Link pending
0001493152-24-007096-xbrl.zip Edgar Link pending
ex10-11.htm Edgar Link pending
ex10-12.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
nxen-20231231.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nxen-20231231_cal.xml Edgar Link unprocessable
nxen-20231231_def.xml Edgar Link unprocessable
nxen-20231231_lab.xml Edgar Link unprocessable
nxen-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable